Bionet Corp. AI Stock Analysis
Bionet Corp. (1784) AI Stock Analysis
Bionet Corp.
(TPEx:1784)
Bionet scores in the lower-middle range. The primary drag is a sharp deterioration in 2025 earnings quality — flat revenue growth, a swing to an operating loss, halved EBITDA, falling return on equity, and free cash flow nearly wiped out by heavy capital spending. This is compounded by a weak technical picture, with the share price below all major moving averages and a deeply negative MACD, though extremely low RSI and Stochastic readings suggest the stock is oversold and could see a short-term bounce. Valuation adds further caution: a P/E above 40 is hard to justify against shrinking core profitability, only partially offset by a near-2% dividend yield and low beta. Supporting the score is a genuinely strong balance sheet with minimal leverage, durable ~55% gross margins, and operating cash flow that comfortably exceeds reported profit — giving the company time to work through its current investment cycle. Investors should look for a re-acceleration in revenue and a return to operating profitability before the outlook improves.
Bionet Corp. (1784) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.25B
- Dividend Yield
- 1.87%
- Average Volume (3M)
- 74.26K
- Price to Earnings (P/E)
- 39.6
- Beta (1Y)
- 0.81
- Revenue Growth
- 5.41%
- EPS Growth
- -19.02%
- Country
- TW
- Employees
- 80
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Bionet Corp. Business Overview & Revenue Model
Company Description
Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking ser...
Bionet Corp. Financial Statement Overview
Summary
Bionet's balance sheet is its clear strength, with a debt-to-equity ratio of just 0.09 (NT$116M debt vs NT$1.27B equity) and healthy cash conversion — NT$148M of operating cash flow versus NT$51M of net income. Gross margin remains durable near 55%, pointing to real pricing power. However, 2025 performance deteriorated materially: revenue growth stalled to roughly 1.2% after 8.4% in 2024, cost inflation pushed the business to a NT$14M operating loss, EBITDA fell from NT$149M to NT$48M, net margin compressed to 4.2% from 6.8%, and return on equity slipped to 4.0%. Heavy capital spending shrank free cash flow by about 76% to only NT$16M. The company is well capitalized but currently under-earning, with profit reliant on non-operating items rather than core operations.
Income Statement
54NeutralBalance Sheet
72PositiveCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29B | 1.24B | 1.22B | 1.13B | 980.38M | 921.42M |
| Gross Profit | 722.28M | 683.87M | 685.77M | 638.28M | 542.22M | 503.07M |
| EBITDA | 63.56M | 47.87M | 149.09M | 147.10M | 113.97M | 80.41M |
| Net Income | 45.86M | 51.43M | 83.70M | 78.40M | 37.97M | 26.62M |
Balance Sheet | ||||||
| Total Assets | 3.08B | 3.08B | 3.16B | 2.35B | 1.84B | 1.78B |
| Cash, Cash Equivalents and Short-Term Investments | 1.46B | 1.40B | 1.58B | 907.35M | 438.82M | 385.09M |
| Total Debt | 141.63M | 116.27M | 96.43M | 45.01M | 15.25M | 14.52M |
| Total Liabilities | 879.32M | 822.58M | 760.40M | 626.47M | 513.97M | 468.19M |
| Stockholders Equity | 1.23B | 1.27B | 1.33B | 1.19B | 1.08B | 1.10B |
Cash Flow | ||||||
| Free Cash Flow | 96.07M | 15.86M | 73.00M | 126.81M | 61.74M | -2.79M |
| Operating Cash Flow | 195.41M | 148.04M | 176.49M | 153.09M | 94.65M | 13.88M |
| Investing Cash Flow | -89.37M | 35.37M | -778.15M | -409.93M | -2.91M | -4.59M |
| Financing Cash Flow | -70.96M | -169.96M | 605.46M | 333.98M | -51.90M | -15.60M |
Bionet Corp. Peers Comparison
Overall Rating
TW:415564Neutral
TW:417560Neutral- TW:178452Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4155 | 64Neutral | TWD 2.19B | 10.29 | ― | 1.71% | -10.90% | ― |
| TW:4175 | 60Neutral | TWD 2.09B | 12.99 | ― | 6.08% | 2.49% | 5.18% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1784 | 52Neutral | TWD 2.38B | 39.56 | ― | 1.87% | 5.41% | -19.02% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1784 | Bionet Corp. | 47.00 | -50.18 | -51.64% | |
| TW:4155 | Ok Biotech Co., Ltd. | 17.50 | 2.12 | 13.81% | |
| TW:4175 | MedFirst Healthcare Services, Inc. (TW) | 49.35 | -5.02 | -9.23% | |
| TW:6892 | Taiwan Bio Therapeutics Co., Ltd. | 26.05 | -3.65 | -12.30% | |
| TW:6918 | A Plus Biotechnology Co Ltd | 74.70 | -7.94 | -9.60% | |
| TW:6955 | Bonraybio Co. Ltd. | 86.00 | -47.88 | -35.76% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026